

	AVASTIN	LUCENTIS	EYLEA	rolucizumab
Baseline				
Q3 2012	77%	23%	0%	
Q1 2013	50%	29%	21%	
Q2	55%	27%	18%	
Q3	55%	28%	17%	
Q4	51%	28%	21%	
Q1 2014	54%	26%	20%	
Q2	48%	27%	24%	
Q3	52%	26%	22%	
Q4	52%	23%	24%	
Q1 2015	54%	18%	27%	
Q2	46%	21%	33%	
Q3	35%	26%	39%	
Q4	38%	20%	42%	
Q1 2016	35%	21%	44%	
Q2	33%	20%	47%	
Q3	36%	16%	48%	
Q4	39%	19%	42%	
Q1 2017	37%	16%	47%	
Q2	40%	19%	41%	
Q3	43%	20%	37%	
Q4	41%	18%	41%	
Q1 2018	41%	16%	43%	
Q2	41%	19%	40%	
Q3	45%	13%	42%	
Q4	41%	15%	44%	
Q1 2019	35%	14%	51%	
Q2	43%	17%	40%	
Q3	41%	16%	43%	
Q4	42%	16%	42%	
Q1 2020	44%	15%	37%	4%
Q2	40%	22%	34%	4%
Q3	41%	14%	41%	4%
Q4	42%	16%	39%	3%
Q2 2021	37%	15%	46%	2%

Mylan v. Regeneron
 IPR2021-00881
 U.S. Pat. 9,254,338
 Exhibit 2282